Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 278,676 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 278,676 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $24.48, for a total value of $6,821,988.48. Following the completion of the sale, the chief executive officer owned 2,180,518 shares in the company, valued at $53,379,080.64. This represents a 11.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Adaptive Biotechnologies Stock Up 3.8%

Shares of NASDAQ ADPT traded up $0.93 during midday trading on Wednesday, hitting $25.49. The company’s stock had a trading volume of 2,145,752 shares, compared to its average volume of 2,579,911. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The firm has a market capitalization of $4.07 billion, a price-to-earnings ratio of -62.17 and a beta of 2.08. The business’s fifty day simple moving average is $21.75 and its two-hundred day simple moving average is $17.24. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. During the same quarter last year, the company earned ($0.17) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 21.5% compared to the same quarter last year. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Institutional Trading of Adaptive Biotechnologies

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Adaptive Biotechnologies during the second quarter worth approximately $324,735,000. Westfield Capital Management Co. LP purchased a new stake in Adaptive Biotechnologies in the 4th quarter valued at $65,942,000. Price T Rowe Associates Inc. MD raised its position in Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. raised its position in Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Adaptive Biotechnologies by 248.8% during the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after purchasing an additional 2,216,595 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ADPT. Piper Sandler raised their price target on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Guggenheim increased their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Morgan Stanley raised their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. decreased their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.